Retatrutide research overview covering triple GIP/GLP-1/glucagon receptor agonism, phase 2 findings, investigational status, safety and COA verification.
Retatrutide is an investigational single molecule designed to activate GIP, GLP-1 and glucagon receptors. Phase 2 trials have examined body-weight and glycemic outcomes.
The results are promising research signals, not authorization for routine use. Trial participants used a defined investigational product with structured titration, monitoring and eligibility criteria that cannot be transferred to an RUO vial.
Mechanism explains why a compound enters a research conversation. It does not establish that the compound is effective, appropriate or safe for a person.
GIP and GLP-1 receptor activity affects incretin signalling, appetite and glucose regulation; glucagon-receptor activity adds effects on hepatic and energy-metabolism pathways.
The third receptor is not simply “more GLP-1.” It changes both the hypothesis and the safety questions, including heart rate, gastrointestinal tolerance and metabolic monitoring.
These are recurring questions in the published literature. They are research themes, not promised outcomes or personal recommendations.
In Phase 3 TRIUMPH-4 trial data, average weight loss reached 28.7% of body weight at 68 weeks on the 12 mg dose
Trial data suggest increased resting energy expenditure via glucagon receptor activation, distinct from GLP-1-only agonists
Phase 2a sub-study reported liver fat reduction of up to 86% at 12 mg, with 93% of participants reaching normal liver fat levels
Phase 3 T2D trial data show HbA1c reductions of up to 2.0%, with 82% of participants reaching HbA1c ≤6.5% in earlier Phase 2 data
Trial data reported relief from knee osteoarthritis pain and improved physical function scores in a Phase 3 sub-analysis
Trial data show favorable shifts in cardiovascular risk markers: reduced triglycerides, blood pressure, and non-HDL cholesterol
Phase 2 trials in obesity and type 2 diabetes reported substantial changes in study endpoints while also documenting dose-related adverse events, especially gastrointestinal events.
What the evidence cannot answer: These studies establish a reason for phase 3 research. They do not authenticate research-market material, create an approved dose or support unsupervised substitution for authorized treatment.
Open the published batch report and match its COA number to the vial used in your research.
View Retatrutide COAResearch-market naming does not establish identity, concentration or purity. A useful certificate of analysis identifies the batch, analytical method and measured result. Match the COA number to the vial rather than relying on a site-wide percentage or a study of a different product.
Independent verification: every certificate of analysis carries a code you can check yourself at Peptide Test Canada, an independent third-party testing lab — you don't have to take our word for it.
Quantum publishes an individual report for this entry and keeps the broader lab-results archive available for comparison.
Metabolic-drug screening includes current glucose-lowering therapy, pancreatitis and gallbladder history, severe gastrointestinal disease, pregnancy, thyroid/MEN2 context and hydration risk.
Product status: Retatrutide remains investigational and Quantum’s material is supplied for laboratory research only.
The tracker separates baseline screening, titration decisions, tolerance notes, monthly review and metabolic measurements.
Cadence, timing and cycle are owner-draft previews. Dose, dilution, titration, inventory, check-ins and change history remain inside the tracker after purchase.
Concise answers that keep mechanism, evidence, product quality and regulatory status separate.
Retatrutide is an investigational single molecule designed to activate GIP, GLP-1 and glucagon receptors. Phase 2 trials have examined body-weight and glycemic outcomes.
GIP and GLP-1 receptor activity affects incretin signalling, appetite and glucose regulation; glucagon-receptor activity adds effects on hepatic and energy-metabolism pathways.
Phase 2 trials in obesity and type 2 diabetes reported substantial changes in study endpoints while also documenting dose-related adverse events, especially gastrointestinal events. Long-term cardiovascular outcomes, rare risks, maintenance strategies and routine clinical use remain under investigation.
Retatrutide remains investigational and Quantum’s material is supplied for laboratory research only.
This educational page does not provide a protocol. Published exposure, when available, is specific to the studied or authorized product and cannot be transferred to Quantum’s research-use-only material. Use the tracker only as an organizational record, not a substitute for qualified medical care.
Use the individual batch report to verify identity, analytical method, reported purity and COA number. Match that number to the vial; a general purity claim is not batch verification.